← Eichor
Study identifier: NCT05775458 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology

Condition: Brain Tumor, Primary  ·  Sponsor: IRCCS San Raffaele

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. It is essential for regulating cellular metabolism and developmental synaptogenesis, cellular migration, differentiation and death. Recent scientific evidences have demonstrated alteration in Glu synthesis and signaling being directly involved in GBM growth and invasion

This description comes directly from the study's public registry record.

Talk to the study team

Sincinelli Laura  ·  0226436658  ·  sincinelli.laura@hsr.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS San Raffaele Scientific InstituteMilan, Milan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05775458